Best practice

Evaluating the long-term effects of access initiatives on healthcare systems and patients

To improve access to medicine, companies need to understand “what works” and build on progress.

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |